Kenvue Inc. (NYSE:KVUE) Stock Holdings Lifted by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 30.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,992,933 shares of the company's stock after purchasing an additional 2,316,443 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.52% of Kenvue worth $231,137,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Riverview Trust Co acquired a new position in Kenvue during the 3rd quarter worth $30,000. Ashton Thomas Securities LLC acquired a new position in Kenvue during the 3rd quarter worth $35,000. Studio Investment Management LLC grew its holdings in Kenvue by 52.1% during the 2nd quarter. Studio Investment Management LLC now owns 2,468 shares of the company's stock worth $45,000 after acquiring an additional 845 shares in the last quarter. Deseret Mutual Benefit Administrators grew its holdings in Kenvue by 49.7% during the 3rd quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company's stock worth $45,000 after acquiring an additional 651 shares in the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new position in Kenvue during the 2nd quarter worth $61,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Deutsche Bank Aktiengesellschaft raised their price target on shares of Kenvue from $23.00 to $24.00 and gave the stock a "buy" rating in a research report on Wednesday, August 7th. Jefferies Financial Group assumed coverage on shares of Kenvue in a research report on Tuesday, September 24th. They issued a "buy" rating and a $27.00 price target on the stock. Bank of America raised their price target on shares of Kenvue from $24.00 to $27.00 and gave the stock a "buy" rating in a research report on Tuesday, October 22nd. JPMorgan Chase & Co. raised their price target on shares of Kenvue from $24.00 to $25.00 and gave the stock an "overweight" rating in a research report on Friday, October 11th. Finally, Royal Bank of Canada downgraded shares of Kenvue from an "outperform" rating to a "sector perform" rating and set a $24.00 price target on the stock. in a research report on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, Kenvue currently has an average rating of "Hold" and an average price target of $22.64.

Kenvue Price Performance

Shares of KVUE stock traded down $0.05 during midday trading on Friday, reaching $24.08. 7,516,546 shares of the company were exchanged, compared to its average volume of 17,823,225. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46. The company has a market cap of $46.17 billion, a P/E ratio of 43.81, a PEG ratio of 2.19 and a beta of 1.36. The company's 50 day moving average price is $22.94 and its two-hundred day moving average price is $20.99. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.28 EPS for the quarter, topping analysts' consensus estimates of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The company had revenue of $3.90 billion for the quarter, compared to the consensus estimate of $3.92 billion. During the same period in the previous year, the firm earned $0.31 EPS. Kenvue's revenue was down .4% on a year-over-year basis. On average, sell-side analysts expect that Kenvue Inc. will post 1.07 earnings per share for the current year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th were paid a $0.205 dividend. The ex-dividend date was Wednesday, November 13th. This represents a $0.82 annualized dividend and a dividend yield of 3.41%. Kenvue's dividend payout ratio is currently 149.09%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.